Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanc… Ended

2024-512378-91-00 Unresectable or Advanced Melanoma 4 2022-06-24
Clinical trial of MK-1484 given alone and with pembrolizumab in adults with solid tumors Ended

2023-505067-36-00 Advanced or Metastatic Solid Tumors 1 2022-06-22
A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination with Checkpoint Inhibition for the Treatment of Participants wit… Ended

2022-502681-24-00 Relapsed or Refractory Multiple Myeloma 3 2022-06-22
Clinical trial to evaluate the effects of chemotherapy with anthracycline, after radiotherapy, in a group of pediatric and young adult patie… Ended

2024-519135-41-00 Glioblastoma 4 2022-06-21
A Study of the Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination with Venetoclax in AML Ended

2024-516294-78-00 Acute Myeloid Leukemia (AML) 4 2022-06-17
A clinical study that compares a treatment with Iberdomide, Daratumumab and Dexamethasone against a treatment with Daratumumab, Bortezomib, … Ended

2024-510800-35-00 Relapsed or Refractory Multiple Myeloma (RRMM) 5 2022-06-17
A study to test whether different combinations of BI 765063, ezabenlimab, chemotherapy, cetuximab, and BI 836880 help people with head and n… Ended

2024-512799-36-00 head and neck squamous cell carcinoma (HNSCC) 3 2022-06-16
SEQUEL-Breast: a phase 2 study on the combination of alpelisib and fulvestrant after progression on previous therapy with fulvestrant in pat… Ended

2024-514965-20-00 Breast cancer 4 2022-06-02
A Global Study to Assess the Effects of Durvalumab with Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Pati… Ended

2023-503999-24-00 Patients With Locally Advanced (Stage III), Unresectabl 5 2022-06-01
A study to investigate the short- and long-term safety and tolerability of the drug SNDX-5613 in Patients with Relapsed/Refractory Leukemias… Ended

2024-513759-34-00 Relapsed or Refractory Acute Leukemias 7 2022-05-31
This study is to understand how well an investigational drug (called Napabucasin) works when given in combination with chemotherapy treatmen… Ended

2024-518205-17-00 Histologically or cytologically confirmed advanced panc 10 2022-05-27
A multicentre phase II, single arm study of Durvalumab (MEDI 4736) with Carboplatin plus Etoposide for 4 cycles followed by Durvalumab maint… Ended

2024-516157-41-00 Metastatic pulmonary large-cell neuroendocrine carcinom 4 2022-05-27
A research study to evaluate the activity of Sotorasib for the treatment of patients with non-operable non-small cell lung cancer with a KRA… Ended

2024-511268-10-00 Unresectable stage III (IIIA-N2, IIIB, IIIC) KRAS p.G12 4 2022-05-25
IMA401-101 – Treatment of patients with solid tumors with IMA401 TCER®, a bispecific T-cell receptor (Phase I trial); alone or in combinatio… Ended

2023-506854-19-00 Solid Tumors 1 2022-05-19
IFCT-2101 MASTERPROTOCOL ALK : Study of safety and efficacy of brigatinib and carboplatin-pemetrexed combination therapy or brigatinib monot… Ended

2023-510387-13-00 advanced ALK-positive non-small cell lung cancer 4 2022-05-18
A late stage clinical trial to investigate the efficacy and safety of Osimertinib versus Placebo in patients with stage IA2-IA3 non-small ce… Ended

2023-509943-28-00 Stage IA2-IA3 non-small cell lung carcinoma, with EGFR 5 2022-05-18
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA) Ended

2023-508536-64-00 Metastatic Prostate Cancer 9 2022-05-17
A phase 1/1b/2 study of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors. Ended

2023-504363-17-00 Advanced MTAP-null solid tumors 7 2022-05-13
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblasto… Ended

2023-506719-17-00 Glioblastoma 3 2022-05-10
Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant NSCLC according to TP53 mutational status (TEMPLE-2) Ended

2024-517424-18-00 Patients with EGFR mutant NSCLC according to TP53 muta 6 2022-05-10
Genetic vaccine for the treatment of microsatellite unstable solid tumors Ended

2024-514723-42-00 Locally advanced unresectable or metastatic, microsatel 9 2022-05-05
Body surface area-based vs concentration-based dosing of cisplatin for hyperthermic intraperitoneal chemotherapy (HIPEC) in women with advan… Ended

2024-514711-99-00 FIGO stage III high grade serous ovarian cancer, perito 10 2022-05-02
To evaluate the efficacy and safety of regorafenib in patients with refractory primary bone tumors. Ended

2024-514720-17-00 Refractory primary bone tumors 4 2022-04-29
A Phase 3 Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant Ended

2023-508897-27-00 Multiple Myeloma 5 2022-04-28